$Short-course hypofractionated proton beam therapy, incorporating 18F-DOPA PET and contrast-enhanced MRI targeting, for patients aged 65 years and older with newly diagnosed glioblastoma: a single-arm phase 2 trial$

Short-course hypofractionated proton beam therapy, incorporating 18F-DOPA PET and contrast-enhanced MRI targeting, for patients aged 65 years and older with newly diagnosed glioblastoma: a single-arm phase 2 trial

Older patients (aged ≥65 years) with glioblastoma have a worse prognosis than younger patients and a median overall survival of 6–9 months. 3,4-Dihydroxy-6-[18F]fluoro-L-phenylalanine (18F-DOPA) PET sensitively and specifically identifies metabolically active glioblastoma for preferential targeting....

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The lancet oncology 2024-12, Vol.25 (12), p.1625-1634
Hauptverfasser:	Vora, Sujay, Pafundi, Deanna, Voss, Molly, Buras, Matthew, Ashman, Jonathan, Bendok, Bernard, Breen, William, Hu, Leland, Kizilbash, Sani, Laack, Nadia, Liu, Wei, Mahajan, Anita, Mrugala, Maciej, Porter, Alyx, Ruff, Michael, Sio, Terence, Uhm, Joon, Yang, Ming, Brinkmann, Debra, Brown, Paul
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!